Sutro Biopharma (STRO) executive compensation, 2026 proxy

Jane Chung, R.Ph., Chief Executive Officer, was paid $1.6M in 2025, up 9% from $1.4M the year before.

Filed
April 22, 2026
Annual meeting
June 5, 2026
Pay year
2025
Named executives
4
CEO total pay
$1.6M+9% vs prior year
CEO pay in equity
26%$412,680 in awards
Prior say-on-pay support
78%of votes cast
CEO Base Salary
$652,000Jane Chung annual salary for 2025
Say-on-Pay Support
77.7%Prior year shareholder approval rate

How R.Ph. was paid

$1.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary41%Stock awards11%Option awards16%Non-equity incentive30%All other compensation3%

Named executive officers

ExecutiveTotal
Jane Chung, R.Ph.Chief Executive Officer$1,575,930
William J. NewellFormer Chief Executive Officer$1,671,311
Hans-Peter Gerber, Ph.D.Chief Scientific Officer$942,902
Gregory ChowChief Financial Officer$854,522

What changed and why

  • $1.6MJane Chung received total compensation of $1,575,930 in fiscal 2025 following her appointment as Chief Executive Officer.
  • $1.7MWilliam J. Newell stepped down as Chief Executive Officer, receiving total compensation of $1,671,311 including severance benefits.
  • The company maintained a strict policy prohibiting hedging, margin loans, and pledging of common stock by all employees and directors.
  • 77.7%Stockholders approved the previous say-on-pay proposal with a 77.7% support rate at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.